Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Xarelto (rivaroxaban) - Important Safety Information from Bayer AG as approved by the HPRA (Oct 2018)
Notice type:
3rd Party Publications
Date:
04/10/2018
Problem Or Issue:
Important Safety Information communication from Bayer AG: Xarelto (rivaroxaban) - Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement in a prematurely stopped clinical trial.
Important Safety Information - Xarelto (rivaroxaban) (Oct 2018)
« Back
Date Printed: 27/04/2024